MoonLake Immunotherapeutics (MLTX) Interest & Investment Income (2021 - 2022)
MoonLake Immunotherapeutics' (MLTX) quarterly Interest & Investment Income came in at $8431.0 in Q1 2022, down 52.67% year-on-year from $17815.0 in Q1 2021, and up 273.88% quarter-over-quarter from $2255.0 in Q4 2021.
MoonLake Immunotherapeutics (MLTX) Interest & Investment Income (2021 - 2022) Analysis & Trends
MoonLake Immunotherapeutics' Interest & Investment Income history runs 2 years deep, the most recent figure standing at $8431.0 for Q1 2022.
- On a quarterly basis, Interest & Investment Income fell 52.67% year-over-year to $8431.0 in Q1 2022; TTM through Mar 2022 was $18307.0, a N/A change from a year earlier, with the FY2021 full-year figure at $27691.0, up 85.63% from the prior year.
- Interest & Investment Income advanced to $8431.0 in Q1 2022 per MLTX's latest filing, from $2255.0 in the prior quarter.
- Across five years, Interest & Investment Income topped out at $17815.0 in Q1 2021 and bottomed at $1481.0 in Q3 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 27.66 Mn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 114.80 Mn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | -65.80 Mn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | 48.00 Mn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | 19.51 Mn |
| 10 | MoonLake Immunotherapeutics | 1.41 Bn | 1.06 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2022 | 8,431.00 |
| Dec 31, 2021 | 2,255.00 |
| Sep 30, 2021 | 1,481.00 |
| Jun 30, 2021 | 6,140.00 |
| Mar 31, 2021 | 17,815.00 |